PARP inhibitor becomes new treatment option for some men with advanced prostate cancer

Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib, resulting in recent FDA approval.

Read the full article here

Related Articles